Category: Patent Trial & Appeal Board
-
Chinese medical device makers settle six-year pulse oximeter litigation in the U.S.
Beijing Choice and Contec settled their patent infringement dispute for US$1 million, and the defendant has agreed not to sell its fingertip oximeters in the U.S. without signing a licensing agreement first.
-
$847 million patent verdict against Verizon; Ericsson on extended receiving end of $583M part, fighting patent at PTAB jointly with Nokia
Context: Hardly a month passes without a non-practicing entity (NPE) obtaining a patent damages verdict in the hundreds of millions of dollars in U.S. district court (May 11, 2024 ip fray article). What’s new: On Friday (June 28, 2024), a jury in the Eastern District of Texas awarded NPE General Access Solutions $847 million over…
-
More than 95% of Netlist’s $445 million jury verdict against Micron is based on patent claim invalidated by PTAB
Netlist obtained a $445 million damages award from a Texas jury yesterday, but he bulk of it ($425 million) is based on a patent claim the PTAB recently invalidated.
-
Federal Circuit denies fee-shifting with respect to PTAB IPR despite infringement case being exceptionally weak
Two Federal Circuit judges decided (but a district judge sitting by designation disagreed) that challenging a patent-in-suit in the PTAB, even if the IPR petition is brought after an infringement complaint, cannot give rise to fee-shifting.
-
From $67.5M to $142M to $61M: roller-coaster damages award in Samsung SEP case as PTAB invalidates one of two patents
The patent that accounts for more than half of the $142M retrial verdict against Samsung has been invalidated by the PTAB.
-
Supreme Court asked to clarify PTAB invalidation decisions have preclusive effect even if being appealed
The Federal Circuit apparently believes that its own affirmance of a PTAB invalidity finding has preclusive effect (even if the losing side could still petition for rehearing or certiorari), while a final PTAB decision does not.